TSE:TH

Theratechnologies Stock Forecast, Price & News

C$4.21

-0.01 (-0.24 %)

(As of 05/11/2021 12:00 AM ET)

Add

Compare

Today's Range

C$4.03

▼

C$4.23

50-Day Range

C$4.22

▼

C$4.97

52-Week Range

C$2.30

▼

C$5.34

Volume86,227 shs

Average Volume191,255 shs

Market CapitalizationC$398.27 million

P/E RatioN/A

Dividend YieldN/A

BetaN/A

30 days | 90 days | 365 days | Advanced Chart

Receive TH News and Ratings via Email

Sign-up to receive the latest news and ratings for Theratechnologies and its competitors with MarketBeat's FREE daily newsletter.

About Theratechnologies

Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH-1902 for the treatment of triple negative breast cancer; and TH-1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.

Theratechnologies (TSE:TH) Stock Price Passes Below 50-Day Moving Average of $4.46
May 1, 2021 | americanbankingnews.com

Theratechnologies EPS misses by $0.03, misses on revenue - Seeking Alpha
April 14, 2021 | seekingalpha.com

Theratechnologies, Inc. to Host Earnings Call - Benzinga
April 14, 2021 | benzinga.com

Theratechnologies Reports First Quarter 2021 Financial Results and Recent Business Highlights - GlobeNewswire
April 14, 2021 | globenewswire.com

The Week Ahead In Biotech (April 11-17): Avenue Therapeutics FDA Decision and Conference Presentations In The Spotlight - Benzinga
April 10, 2021 | benzinga.com

Theratechnologies Presents New In Vivo Pre-Clinical Data at AACR Demonstrating Significant Anti-Tumor Activity of TH1902 in All Studied Cancer Types - Yahoo Finance
April 10, 2021 | finance.yahoo.com

Theratechnologies Announces Two Strategic Hires to Support its Commercial and Pipeline Assets - GlobeNewswire
March 29, 2021 | globenewswire.com

Theratechnologies (THTX) Announces First Patient Dosed in Phase 1 Clinical Trial of TH1902 for Sortilin Positive Solid Tumors - StreetInsider.com
March 26, 2021 | streetinsider.com

Theratechnologies Announces First Patient Dosed in Phase 1 Clinical Trial of TH1902 for Sortilin Positive Solid Tumors - Yahoo Finance
March 25, 2021 | finance.yahoo.com

Dosing underway in Theratechnologies study of TH1902 in SORT1+ solid tumors - Seeking Alpha
March 24, 2021 | seekingalpha.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange TSE

Industry Biotechnology

Sub-IndustryN/A

SectorMedical

Current SymbolTSE:TH

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.theratech.com

Phone+1-514-3367800

Employees54

Year FoundedN/A

Sales & Book Value

Annual SalesC$65.76 million

Price / Sales6.06

Cash FlowC$0.59 per share

Price / Cash Flow7.15

Book ValueC$0.43 per share

Price / Book9.77

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Debt

Debt-to-Equity Ratio138.02

Current Ratio2.59

Quick Ratio1.73

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E Growth-63.18

Miscellaneous

Outstanding Shares94,601,000

Market CapC$398.27 million

Next Earnings Date7/21/2021 (Estimated)

OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

0.68 out of 5 stars

1.0 Analyst's Opinion

Consensus Rating
Theratechnologies has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of C$3.75, Theratechnologies has a forecasted downside of 10.9% from its current price of C$4.21.
Amount of Analyst Coverage
Theratechnologies has only been the subject of 1 research reports in the past 90 days.

2.4 Community Rank

Outperform Votes
Theratechnologies has received 266 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Theratechnologies has received 299 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Theratechnologies has received 52.92% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Theratechnologies and other stocks. Vote “Outperform” if you believe TH will outperform the S&P 500 over the long term. Vote “Underperform” if you believe TH will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Theratechnologies does not currently pay a dividend.
Dividend Growth
Theratechnologies does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Theratechnologies insiders have not sold or bought any company stock.

0.0 Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Theratechnologies is -11.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Theratechnologies is -11.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Growth Ratio
Due to a projected decrease in earnings for Theratechnologies, their PEG ratio cannot be calculated.
Price to Book Value per Share Ratio
Theratechnologies has a P/B Ratio of 9.77. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Theratechnologies (TSE:TH) Frequently Asked Questions

Is Theratechnologies a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Theratechnologies in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Theratechnologies stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TH, but not buy additional shares or sell existing shares.
View analyst ratings for Theratechnologies or view top-rated stocks.

What stocks does MarketBeat like better than Theratechnologies?

Wall Street analysts have given Theratechnologies a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Theratechnologies wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Theratechnologies' next earnings date?

Theratechnologies is scheduled to release its next quarterly earnings announcement on Wednesday, July 21st 2021.
View our earnings forecast for Theratechnologies.

How were Theratechnologies' earnings last quarter?

Theratechnologies Inc. (TSE:TH) released its quarterly earnings data on Thursday, February, 25th. The company reported ($0.09) earnings per share for the quarter. The firm had revenue of $24.93 million for the quarter.
View Theratechnologies' earnings history.

How has Theratechnologies' stock been impacted by Coronavirus?

Theratechnologies' stock was trading at C$3.00 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, TH shares have increased by 40.3% and is now trading at C$4.21.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for TH?

2 brokers have issued 1 year price targets for Theratechnologies' shares. Their forecasts range from C$3.75 to C$3.75. On average, they anticipate Theratechnologies' stock price to reach C$3.75 in the next year. This suggests that the stock has a possible downside of 10.9%.
View analysts' price targets for Theratechnologies or view top-rated stocks among Wall Street analysts.

Who are Theratechnologies' key executives?

Theratechnologies' management team includes the following people:

Mr. Philippe Dubuc M.B.A., MBA, Sr. VP & CFO (Age 54, Pay $318.54k)
Mr. Jocelyn Lafond, VP of Legal Affairs & Corp. Sec. (Age 53, Pay $281.34k)
Dr. Christian Marsolais, Sr. VP & Chief Medical Officer (Age 58, Pay $357.28k)
Mr. Conor M. Walshe, Gen. Mang. of Theratechnologies Europe Limited (Age 48, Pay $370.51k)
Leah Gibson, Sr. Director of Investor Relations
Mr. Denis Boucher B.A., L.L.B., VP of Communications & Corp. Affairs (Age 55)

Who are some of Theratechnologies' key competitors?

Some companies that are related to Theratechnologies include BioAtla (BCAB), Edgewise Therapeutics (EWTX), Cullinan Oncology (CGEM), Concordia International (CXR), Nurix Therapeutics (NRIX), Trillium Therapeutics (TRIL), PureTech Health (PRTC), Kinnate Biopharma (KNTE), Stem (STEM), Silverback Therapeutics (SBTX), Vor Biopharma (VOR), Pharming Group (PHAR), Oxford Biomedica (OXB), Connect Biopharma (CNTB) and iTeos Therapeutics (ITOS).
View all of TH's competitors.

What other stocks do shareholders of Theratechnologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Theratechnologies investors own include Stars Group (TSGI), Theratechnologies (THERF), BCE (BCE), ProMetic Life Sciences (PLI), Teranga Gold (TGZ), Endeavour Mining (EDV), Nemaska Lithium (NMX), Shopify (SHOP), United Therapeutics (UTHR) and (AVO.TO) (AVO).

What is Theratechnologies' stock symbol?

Theratechnologies trades on the Toronto Stock Exchange (TSX) under the ticker symbol "TH."

How do I buy shares of Theratechnologies?

Shares of TH and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is Theratechnologies' stock price today?

One share of TH stock can currently be purchased for approximately C$4.21.

How much money does Theratechnologies make?

Theratechnologies has a market capitalization of C$398.27 million and generates C$65.76 million in revenue each year.

How many employees does Theratechnologies have?

Theratechnologies employs 54 workers across the globe.

What is Theratechnologies' official website?

The official website for Theratechnologies is www.theratech.com.

Where are Theratechnologies' headquarters?

Theratechnologies is headquartered at 2015 Peel St 5th Floor, MONTREAL, QC H3A 1T8, Canada.

How can I contact Theratechnologies?

Theratechnologies' mailing address is 2015 Peel St 5th Floor, MONTREAL, QC H3A 1T8, Canada. The company can be reached via phone at +1-514-3367800.

This page was last updated on 5/11/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here